Pediatric Clinical Trials

Brain/CNS

Protocol COG ACNS1831
Cancer Type: Low-Grade Glioma
Fast Facts

A Phase III Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in 
Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Patients must be ≥ 2 Years and ≤ 21 Years at the Time of Enrollment.

Protocol COG ACNS1833
Cancer Type: Low-Grade Glioma
Fast Facts

ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment on ACNS1833 Step 0.

Protocol COG ACNS1931
Cancer Type: Low Grade Glioma
Fast Facts

COG-ACNS1931: A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Feasibility Phase - Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≥ 2 years and ≤ 25 years of age at the time of enrollment.
All patients > 21 years of age at the time of enrollment must have had initial diagnosis of low-grade glioma by 21 years of age.

 

Protocol COG ACNS2021
Cancer Type: CNS - Germ Cell
Fast Facts

COG ACNS2021

A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

Patients must be greater than or equal to 3 years and less than 30 years at the time of study enrollment.

Protocol COG ACCL2031
Cancer Type: CNS
Fast Facts

COG ACCL2031

A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Cancer Care Delivery (CCDR)

Please check out the rare protocol list to locate other studies within this disease site.

Cancer Control

Protocol COG ALTE03N1
Cancer Type: Multi-site Cancer Control
Fast Facts

Key Adverse Events After Childhood Cancer

Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.

Protocol COG ALTE07C1
Cancer Type: Multi-Site Cancer Control
Fast Facts

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Gastrointestinal

Please check out the rare protocol list to locate other studies within this disease site.

Genitourinary

Protocol COG AREN03B2
Cancer Type: Renal-Biology
Fast Facts

Renal Tumors Classification, Biology, and Banking Study 

Patients must be < 30 Years Old at the Time of Diagnosis

Protocol COG AREN1921
Cancer Type: Wilms
Fast Facts

COG-AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Patients must be ≤ 30 years old at study enrollment.

Please check out the rare protocol list to locate other studies within this disease site.

Germ Cell

Protocol COG AGCT1531
Cancer Type: Germ Cell
Fast Facts

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.

Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.

Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment. 

Protocol COG AGCT1532
Cancer Type: Germ Cell
Fast Facts

Phase III Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Age ≥ 11 Years and ≤ 45 Years on the Date of Randomization

Protocol COG ACNS2021
Cancer Type: CNS - Germ Cell
Fast Facts

COG ACNS2021

A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

Patients must be greater than or equal to 3 years and less than 30 years at the time of study enrollment.

Please check out the rare protocol list to locate other studies within this disease site.

Leukemia

Protocol COG ACCL1931
Cancer Type: ALL
Fast Facts

COG-ACCL1931: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy

Age: ≥15 and <40 years at time of diagnosis.

Protocol COG AALL2121
Cancer Type: leukemia
Fast Facts

COG-AALL2121: A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia

Age: Patients must be 1 month to < 6 years old at the time of study enrollment and must have had initial diagnosis of leukemia at < 2 years old.

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG AALL1621
Cancer Type: Relapsed Refractory CD22 B-ALL
Fast Facts

A Phase II Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Patients must be ≥1 Year and < 22 Years of Age at the Time of Enrollment.

Protocol COG AALL1631
Cancer Type: Ph+ ALL
Fast Facts

International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Age:  > 1 Year and < 21 Years at ALL Diagnosis

Protocol COG AALL1731
Cancer Type: B-ALL, B-LLy
Fast Facts

A Phase III Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Patients must be ≥ 365 Days and < 10 Years of Age (B-ALL Patients without DS)

Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-ALL Patients with DS)

Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-LLy Patients with or without DS

 

Protocol COG AALL1732
Cancer Type: B-ALL, B-LLy
Fast Facts

A Phase III Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL,Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Patients must be > 365 Days and < 25 Years of Age

Protocol COG AAML18P1
Cancer Type: Chronic Myeloid Leukemia
Fast Facts

COG AAML18P1

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Patient must have been diagnosed with CML-CP at less than 18 years of age

Patient mustbe less than 25 years of age at enrollment

Protocol COG APAL2020SC
Cancer Type: Relapsed Leukemia
Fast Facts

COG APAL2020SC

Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

Patients must be less than 22 years of age at the time of study enrollment.

Please check out the rare protocol list to locate other studies within this disease site.

Lymphoma

Protocol COG AHOD2131
Cancer Type: Classic Hodgkin Lymphoma
Fast Facts

COG-AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Patients must be 5 to 60 years of age at the time of enrollment.

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG ANHL1931
Cancer Type: Lymphoma
Fast Facts

COG ANHL1931

A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

This is an AYA protocol  ≥ 2 years

Please check out the rare protocol list to locate other studies within this disease site.

Multisite

Protocol COG AGCT1531
Cancer Type: Germ Cell
Fast Facts

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.

Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.

Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment. 

Protocol COG APEC14B1
Cancer Type: All patients
Fast Facts

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.

Protocol COG ALTE03N1
Cancer Type: Multi-site Cancer Control
Fast Facts

Key Adverse Events After Childhood Cancer

Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.

Protocol COG ALTE05N1
Cancer Type: Multisite Long Term Follow-up
Fast Facts

Umbrella Long-Term Follow-Up Protocol

Only Available to Patients Already Enrolled on a COG Intervention Protocol.

Protocol COG ALTE07C1
Cancer Type: Multi-Site Cancer Control
Fast Facts

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Protocol COG APEC1621 – MATCH Protocol SC
Cancer Type: Screening
Fast Facts

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

 

Protocol COG APEC1621 - MATCH
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol

Protocol COG APEC1621 - MATCH Protocol F
Cancer Type: Molecular

COG APEC1621F

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG ACCL21C2
Cancer Type: Multi-site Cancer Control
Fast Facts

COG-ACCL21C2: Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer

≥6 months and ≤37 years of age at time of enrollment

Protocol COG ANHL2121
Cancer Type: LCH
Fast Facts

COG-ANHL2121: Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

Age: 180 days- <22 years (at time of study enrollment).

Please check out the rare protocol list to locate other studies within this disease site.

Neuroblastoma

Please check out the rare protocol list to locate other studies within this disease site.

Sarcoma

Protocol COG-ARST2031
Cancer Type: High Risk Rhabdomyosarcoma (HR-RMS)
Fast Facts

COG ARST2031

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)

Patients must be ≤ 50 years of age at the time of enrollment.

Protocol COG AOST2031
Cancer Type: Osteosarcoma
Fast Facts

COG AOST2031

A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Patients must be < 50 years at the time of enrollment

Protocol COG ARST2032
Cancer Type: Rhabdomyosarcoma
Fast Facts

COG- ARST2032: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma

Patients must be ≤ 21 years at the time of enrollment.

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.